Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoSil MedicalASX:OSL -1.88%48 Cash-to-Debt is 67.98 as of Dec. 2025, which is 29% below its 10-year median of 96.12. GuruFocus rates ASX:OSL with a GF Score™ of 48/100 and a GF Value™ of A$2.92 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 849 Medical Devices & Instruments companies, OncoSil Medical ranks better than 87.51% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OncoSil Medical's cash to debt ratio for the quarter that ended in Dec. 2025 was 67.98.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, OncoSil Medicalcould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for OncoSil Medical's Cash-to-Debt or its related term are showing as below:
ASX:OSL'
s Cash-to-Debt Range Over the Past 10 Years
Min: 16.49 Med: 96.12 Max: No Debt
Current: 67.98
During the past 13 years, OncoSil Medical's highest Cash to Debt Ratio was No Debt. The lowest was 16.49. And the median was 96.12.
ASX:OSL's Cash-to-Debt is ranked better than 87.51% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 1.69
vs ASX:OSL: 67.98
OncoSil Medical (ASX:OSL) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
OncoSil Medical Cash-to-Debt Related Terms
OncoSil Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for OncoSil Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Medical Devices subindustry, OncoSil Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoSil Medical Cash-to-Debt vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, OncoSil Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where OncoSil Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoSil Medical (ASX:OSL) has a Cash-to-Debt of 67.98 as of Dec. 2025. This is 29% below median its historical median of 96.12. Over the past decade, OncoSil Medical's Cash-to-Debt has ranged from 16.49 to 10,000.00. According to the industry distribution chart, OncoSil Medical ranks #106 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 12.5%.
Is OncoSil Medical's Cash-to-Debt too high?
OncoSil Medical's current Cash-to-Debt of 67.98 is 29% below median its 10-year median of 96.12. Over the past 10 years, this metric has ranged from a low of 16.49 to a high of 10,000.00. The Medical Devices & Instruments industry median Cash-to-Debt is 1.69. OncoSil Medical's value of 67.98 is 3922.5% above this industry median. Based on the distribution chart, OncoSil Medical ranks #106 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, OncoSil Medical has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OncoSil Medical's Cash-to-Debt compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, OncoSil Medical ranks #106 out of 849 companies for Cash-to-Debt. This places OncoSil Medical in the top 13% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 1.69. OncoSil Medical's value of 67.98 is 3922.5% above this benchmark. Historically, OncoSil Medical's own Cash-to-Debt has ranged from 16.49 to 10,000.00 over the past decade. While the company's 10-year median is 96.12 vs. the industry median of 1.69, OncoSil Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Devices & Instruments company?
The median Cash-to-Debt among Medical Devices & Instruments companies is 1.69, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. OncoSil Medical's current Cash-to-Debt of 67.98 is 3922.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Cash-to-Debt is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSil Medical's current Cash-to-Debt is 67.98, which is 29% below median its own 10-year median of 96.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSil Medical stock overvalued right now?
Based on GuruFocus' analysis, OncoSil Medical (ASX:OSL) is currently considered Possible Value Trap. The stock's GF Value™ is A$2.92, compared to a current price of A$1.31 — trading 55.3% below its estimated fair value. The current Cash-to-Debt is 67.98, which is 29% below median its 10-year median of 96.12 and 3922.5% above the Medical Devices & Instruments industry median of 1.69. OncoSil Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For OncoSil Medical (ASX:OSL), the current Cash-to-Debt is 67.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoSil Medical (ASX:OSL) Overvalued in 2026?
Based on GuruFocus' analysis, OncoSil Medical stock appears to be undervalued.
The current stock price of A$1.31 is trading 55.3% below its estimated GF Value™ of A$2.92.
GuruFocus considers OncoSil Medical to be Possible Value Trap.
Key valuation signals for ASX:OSL:
Cash-to-Debt: 67.98 (29% below median its 10-year median of 96.12)
GF Value™: A$2.92 vs. price of A$1.31 (55.3% below fair value)
Industry Position: 3922.5% above the Medical Devices & Instruments median (#106 of 849)
No single metric tells the full story. See the ASX:OSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoSil Medical Ltd is a medical device company. It is engaged in the development and commercialization of its product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. It operates in one segment. the device development for new medical treatments. Geographically, the company derives its maximum revenue from Europe and the rest from Australia and New Zealand.
48GF Score
Get the complete analysis for ASX:OSL
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:OSL has been successfully added to your 
